Plasmodium falciparum cGMP-Dependent Protein Kinase – A Novel Chemotherapeutic Target

David Rotella, John Siekierka, Purnima Bhanot

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


The primary effector of cGMP signaling in Plasmodium is the cGMP-dependent protein kinase (PKG). Work in human-infective Plasmodium falciparum and rodent-infective Plasmodium berghei has provided biological validation of P. falciparum PKG (PfPKG) as a drug target for treating and/or protecting against malaria. PfPKG is essential in the asexual erythrocytic and sexual cycles as well as the pre-erythrocytic cycle. Medicinal chemistry efforts, both target-based and phenotype-based, have targeted PfPKG in the past few years. This review provides a brief overview of their results and challenges.

Original languageEnglish
Article number610408
JournalFrontiers in Microbiology
StatePublished - 3 Feb 2021


  • Plasmodium
  • cGMP signaling
  • kinase
  • malaria
  • second messenger


Dive into the research topics of 'Plasmodium falciparum cGMP-Dependent Protein Kinase – A Novel Chemotherapeutic Target'. Together they form a unique fingerprint.

Cite this